Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2012. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on share capital and treasury holdings.
- Shares Purchased: 1,400,000 Ordinary Shares on June 14, 2012.
- Price Range: Highest price paid was 1,462.5 pence per share; lowest was 1,445.0 pence per share.
- Treasury Holdings (Settled): 461,157,927 shares (8.44% of total issued share capital).
- Treasury Holdings (Including Unsettled): 465,507,927 shares (9.30% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,004,384,260 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,400,000 shares on June 14, 2012. This transaction increased the company's treasury holdings to 9.30% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure under the Financial Services Authority's Disclosure and Transparency Rules regarding share ownership changes.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (461,157,927 settled vs. 465,507,927 including unsettled).
- Confirm the percentage of total voting rights held in Treasury (9.30%).
- Check the number of shares in issue excluding treasury shares (5,004,384,260) for disclosure threshold calculations.
- Note that this filing does not contain operational or financial performance data.